APL-102

N/A

Report date: 2025/03/16 20:00:05

NME

Base Information

Drug NameAPL-102

Drug Alias NameAPL-102CBT-102

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionMitogen-activated protein kinase inhibitorsColony stimulating factor 1 receptor inhibitorsVascular endothelial growth factor receptor antagonists +[7]

TargetsMitogen-activated protein kinaseColony stimulating factor 1 receptorVascular endothelial growth factor receptor +[7]

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesApollomics Inc

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A

Inactive CompaniesApollomics Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A